Astonea Labs IPO Listing: Stock lists at 1.81% premium on BSE SME

Astonia Labs IPO Debuts with Modest Gains as Company Eyes Global Growth

Astonia Labs, a contract manufacturer of pharmaceutical and cosmetic products, made its stock market debut today on the BSE SME platform.

The company’s ₹37.67 crore initial public offering (IPO) concluded with a modest listing gain, signaling cautious optimism among investors.

Despite mixed subscription figures, Astonia’s strong financial performance and international expansion plans indicate long-term growth potential.

IPO Overview: A Modest but Positive Start

Astonia Labs’ IPO, which was open for subscription from May 27 to May 29, 2025, received a lukewarm response overall, particularly from institutional investors.

The issue was priced at ₹135 per share, and the stock listed on the BSE SME at ₹137.45, translating to a listing premium of 1.81%.

After the initial listing, the share price saw an upward swing, touching an intraday high of ₹140.00.

However, as is typical with debut-day volatility, profit booking pulled the price down to the issue price of ₹135.00 during the session.

The stock eventually closed the day at ₹137.00, offering IPO investors a net gain of 1.48% on the first trading day.

While not a blockbuster debut, the positive listing reflects a degree of confidence in the company’s fundamentals, especially given the challenging sentiment in the broader SME segment.

Subscription Details: Mixed Response from Market Participants

The IPO was subscribed 1.79 times overall, indicating moderate demand. A closer look at the subscription data reveals uneven participation across investor categories:

• Qualified Institutional Buyers (QIBs): Subscribed 0.70x
• Non-Institutional Investors (NIIs): Subscribed 5.60x
• Retail Investors: Subscribed 1.69x

The underwhelming response from institutional investors contrasts with the enthusiastic participation from HNIs and retail investors.

This could be attributed to the company’s SME classification and relatively small issue size, which often see limited QIB interest.

The public issue comprised 27.90 lakh fresh equity shares with a face value of ₹10 each.

Use of IPO Proceeds: Strategic Growth Initiatives

Astonia Labs has clearly outlined its deployment strategy for the IPO proceeds, focusing on expansion, modernization, and market penetration. Here’s how the ₹37.67 crore raised will be utilized:

• ₹1.29 crore – International expansion, including registration in Bolivia, South America, to strengthen its overseas footprint
• ₹5.23 crore – Setting up new production facilities and upgrading existing ones with advanced machinery
• ₹4.95 crore – Aggressive marketing and branding campaigns to enhance product visibility and sales
• ₹68.4 lakh – Investment in IT infrastructure, including hardware and software upgrades for operational efficiency
• ₹19.75 crore – Working capital requirements to support growing operations
• Balance funds – For general corporate purposes and contingencies

This strategic allocation reflects the company’s intent to balance domestic consolidation with global expansion, particularly in emerging markets like South America.

About Astonia Labs: A Rising Star in Contract Manufacturing

Founded in 2017, Astonia Labs operates in the pharmaceutical and cosmetology space, offering contract manufacturing services to various brands in India and abroad.

The company also provides support services such as raw material sourcing, formulation development, and product packaging—making it a comprehensive service provider in the sector.

Its current portfolio includes notable in-house brands such as Glow Up and Regero, both targeting the skincare and wellness market.

The company is gearing up to launch a new product line under the Avicel brand, aimed at further strengthening its presence in the premium cosmetic segment.

In addition to its domestic operations, Astonia Labs has been increasingly focusing on overseas markets. Its move to register operations in Bolivia marks the beginning of a larger plan to expand into Latin America, leveraging cost-effective manufacturing and growing demand for affordable healthcare and personal care products.

Financial Performance: A Remarkable Growth Story

Astonia Labs’ financial track record presents a compelling case for investors looking at long-term potential. Over the last three financial years, the company has delivered significant improvements in profitability and revenue growth.

• FY 2021–22: Net profit stood at ₹25 lakh
• FY 2022–23: Net profit increased to ₹67 lakh
• FY 2023–24: Net profit surged to ₹3.81 crore

This translates to a 15x increase in net profit over just two years—a testament to operational efficiency, rising demand, and product diversification.

On the revenue front, Astonia Labs clocked ₹80.29 crore in FY 2023–24, growing at a compound annual growth rate (CAGR) of over 63%. The momentum has continued into FY 2024–25, with the company posting:

• Revenue (April–December 2024): ₹69.69 crore
• Net Profit (April–December 2024): ₹4.10 crore

If this trajectory sustains, the company is poised to surpass its previous annual performance significantly.

Outlook: Modest Start, Promising Future

While the listing gains were modest, Astonia Labs’ growth story is far from ordinary. The company operates in a sector that’s both resilient and recession-proof, with demand for pharmaceutical and personal care products expected to rise globally.

Its foray into international markets and steady financial performance make it a strong candidate for long-term value creation.

Moreover, the company’s emphasis on technological upgrades, brand development, and market diversification positions it well to capitalize on both domestic and international opportunities.

The fact that the IPO proceeds are being invested directly into business expansion, rather than debt repayment or promoter exits, adds credibility to the company’s growth ambitions.

Final Thoughts

Astonia Labs’ IPO listing may not have made headlines with astronomical gains, but its fundamentals, financial health, and global aspirations make it a company to watch in the SME space.

As it executes its growth strategy—backed by a solid manufacturing base and an expanding product portfolio—investors could see value unfold over the medium to long term.

With increasing global demand for affordable and quality contract-manufactured products, Astonia Labs is well-positioned to scale new heights in the coming years.